Truxima is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy

INN:

Subtype:

Follicular Lymphoma (FL)

License:

EMA

Class:

CD20 monoclonal antibody

Newly Diagnosed

SmPC: https://www.medicines.org.uk/emc/medicine/33201

 

1. Approved Labelling

Truxima is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.

 

2. Treatment Regimen

The recommended dose of Truxima in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: 375 mg/m2 body surface area per cycle, for up to 8 cycles.

Truxima should be administered on day 1 of each chemotherapy cycle, after intravenous administration of the glucocorticoid component of the chemotherapy if applicable.

 

3. AE/Warnings

Please see section 4.4 of the SmPC

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.